Show simple item record

dc.contributor.authorHaslam, Colin
dc.contributor.authorTsitsianis, N.
dc.contributor.authorGleadle, Pauline
dc.date.accessioned2012-04-10T13:58:18Z
dc.date.available2012-04-10T13:58:18Z
dc.date.issued2011-07
dc.identifier.citationHaslam , C , Tsitsianis , N & Gleadle , P 2011 , UK bio pharma : Innovation re invention and capital at risk . Institute of Chartered Accountants of Scotland . < http://icas.org.uk/haslam/ >
dc.identifier.isbn978-1-904574-79-8
dc.identifier.urihttp://hdl.handle.net/2299/8258
dc.description.abstractSmall and medium enterprise (SME) bio-pharmas play a significant role in the development of a knowledge-based competitive economy because they act as an incubator of creativity for the development of pharmabased products which they steer towards regulatory approval. Their contribution is predominantly the development of new pharmaceutical products which can then be licensed or sold on to big-pharma.en
dc.format.extent57
dc.format.extent1698243
dc.language.isoeng
dc.publisherInstitute of Chartered Accountants of Scotland
dc.titleUK bio pharma : Innovation re invention and capital at risken
dc.contributor.institutionDepartment of Accounting, Finance and Economics
dc.contributor.institutionSocial Sciences, Arts & Humanities Research Institute
dc.contributor.institutionFinance and Accounting Research Unit
dc.contributor.institutionCentre for Research on Management, Economy and Society
dc.contributor.institutionHertfordshire Business School
dc.identifier.urlhttp://icas.org.uk/haslam/
rioxxterms.typeConsultancy Report
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record